WILMINGTON, Del. / Aug 22, 2023 / Business Wire / Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September:
The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.
About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.
| Last Trade: | US$93.48 |
| Daily Change: | 0.89 0.96 |
| Daily Volume: | 1,674,971 |
| Market Cap: | US$18.250B |
October 30, 2025 October 27, 2025 October 25, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
